Drugs / TRU-015
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00521638 | Sep 2007 → Apr 2008 | B-cell non-Hodgkin lymphoma | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00479622 | Aug 2007 → May 2008 | systemic lupus erythematosus | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00634933 Comparator | Mar 2008 → Feb 2010 | rheumatoid arthritis | Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRU-015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00521638 ↗ |
| Known as | Pf-5212374 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297845 ↗ |
| Route | Intravenous | “Intravenous administration” NCT00521638 ↗ |
| Target | MS4A1 | “B-lymphocyte antigen CD20 binding agent” CHEMBL4297845 ↗ |